Hematolymphoid Screening Panel Multiparametric Flow Cytometry

• Description of Test:

  The 10-color Hematolymphoid Screening Panel provides a comprehensive approach for evaluating bone marrow and peripheral blood samples for the presence or absence of hematolymphoid malignancies. The panel characterizes and identifies all major white blood cell lineages and identifies all major types of hematopoietic neoplasia. Biomarker selection follows the 2006 Bethesda Consensus¹ for immunophenotypic analysis of hematolymphoid neoplasia with additions chosen by our internal hematopathologist based on recent literature including the 2017 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.^2-8

  This panel not only provides evaluation and monitoring of patients with hematological malignancy but provides a wide array of applications due to its comprehensive biomarker selection.

• Overview:

  Biomarkers in the Screening Panel

  CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD23, CD33, CD34, CD38, CD45, CD56, CD57, CD64, CD71, CD117, CD123, HLA-DR, Kappa, Lambda, and TCR Gamma/Delta.

Service Details

• Indications for Testing:
  • Classifying Acute Leukemia
  • Diagnosing and Classifying B cell Disorders 
  • Evaluating T cell and NK disorders
  • Evaluating Plasma Cell Dyscrasias

   

   

• Turnaround Time:
  24-48 hours
• Specimen Requirements:
  • 2-4 mL of bone marrow or peripheral blood in EDTA or Sodium Heparin
• Specimen Storage Conditions:

  2-8 °C up to 7 days

• Specimen Shipping Conditions:
  • Ambient or Cool; do not freeze
• Locations Where Test is Performed:
  • San Diego, California, USA – LabPMM, LLC
  • Shanghai, China – Invivoscribe Tech